{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:28:44Z","timestamp":1740130124355,"version":"3.37.3"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"French National Institute for Health and Medical Research"},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French National Agency for Research on AIDS and Viral Hepatitis"},{"DOI":"10.13039\/501100003323","name":"ANRS","doi-asserted-by":"publisher","award":["ANRS-163 ETRAL"],"award-info":[{"award-number":["ANRS-163 ETRAL"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Sharp & Dohme and Janssen"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The ANRS-163 ETRAL trial, a switch study to an etravirine 200\u2009mg\/raltegravir 400\u2009mg twice-daily regimen in 165 patients with HIV-1 infection, showed durable efficacy until Week 96. The aim of this work was to investigate in detail the virological rebounds (VRs), defined as at least one plasma HIV viral load (VL) &amp;gt;50\u2009copies\/mL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Quantification of HIV-DNA level was assessed at baseline, Week 48 and Week 96 (n\u2009=\u2009157). VLs were measured in seminal plasma at Week 48 (n\u2009=\u200926). Genotypic resistance testing by ultra-deep sequencing (UDS) for reverse transcriptase (RT) and integrase regions was performed at baseline and at the time of VR.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In this study, 19 patients experienced VR, with 2 patients having virological failure (VF; two consecutive VLs &amp;gt;50\u2009copies\/mL). For the first patient with VF, UDS detected minority resistant variants only in RT (K103N, 9.6%; Y181C, 4.9%) at baseline. Some RT variants became dominant at VF (K101E, 86.3%; Y181C, 100.0%; G190A, 100.0%) and others emerged in integrase (Y143C, 2.4%; Q148R, 6.2%; N155H, 18.8%). For the second patient with VF, neither RT nor integrase mutations were detected at baseline and VF. Median HIV-DNA level was similar at baseline, Week 48 and Week 96 (2.17, 2.06 and 2.11 log10\u2009copies\/106\u2009cells, respectively). Only one patient had a detectable seminal HIV VL (505\u2009copies\/mL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The dual etravirine\/raltegravir regimen as maintenance therapy was effective and the emergence of mutations in cases of VF was similar to that seen in other dual-regimen studies. No HIV-DNA level modification was evidenced by Week 96.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkaa090","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T20:16:18Z","timestamp":1582575378000},"page":"1943-1949","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of viral rebounds on dual etravirine\/raltegravir maintenance therapy (ANRS-163 ETRAL trial)"],"prefix":"10.1093","volume":"75","author":[{"given":"Cathia","family":"Soulie","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, laboratoire de virologie, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambert","family":"Assoumou","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Basma","family":"Abdi","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, laboratoire de virologie, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Sayon","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, laboratoire de virologie, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7619-4321","authenticated-orcid":false,"given":"Thuy","family":"Nguyen","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, laboratoire de virologie, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re \u2013 Service de maladies infectieuses, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydie","family":"Beniguel","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Ferre","sequence":"first","affiliation":[{"name":"Service de Virologie, CHU Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chakib","family":"Alloui","sequence":"first","affiliation":[{"name":"AP-HP, H\u00f4pital Avicennes, Service de Virologie, Bobigny, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Montes","sequence":"first","affiliation":[{"name":"Service de Virologie, CHU Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Avettand-Fenoel","sequence":"first","affiliation":[{"name":"AP-HP, H\u00f4pital Necker, Service de Virologie, Institut Cochin - CNRS 8104\/INSERM U1016\/Universit\u00e9 Paris Descartes, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Delaugerre","sequence":"first","affiliation":[{"name":"AP-HP, H\u00f4pital Saint Louis, Service de Virologie, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Descamps","sequence":"first","affiliation":[{"name":"Sorbonne Paris Cit\u00e9, INSERM, IAME, UMR 1137, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat-Claude Bernard, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Martinez","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit Hospital Clinic, Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Reynes","sequence":"first","affiliation":[{"name":"CHU Montpellier, D\u00e9partement de maladies infectieuses, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Peytavin","sequence":"first","affiliation":[{"name":"AP-HP, Laboratoire de Pharmacologie-Toxicologie, H\u00f4pital Bichat-Claude Bernard and IAME, UMR 1137, Sorbonne Paris Cit\u00e9 and INSERM, Universit\u00e9 Paris Diderot, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Costagliola","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Katlama","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re \u2013 Service de maladies infectieuses, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Calvez","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, laboratoire de virologie, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Genevi\u00e8ve","family":"Marcelin","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, AP-HP, H\u00f4pitaux Universitaires Piti\u00e9 Salp\u00eatri\u00e8re - Charles Foix, laboratoire de virologie, F75013 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the ANRS-163 ETRAL study group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Bottero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bouchaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Chidiac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudine","family":"Duvivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Goujard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"del Mar Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Morlat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alissa","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Poizot-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Raffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Reynes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Salmon-C\u00e9ron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Antoine","family":"Valantin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"2020061904535071600_dkaa090-B1","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkz224","article-title":"Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study","volume":"74","author":"Katlama","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020061904535071600_dkaa090-B2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/phar.2242","article-title":"Lack of a clinically significant pharmacokinetic interaction between etravirine and raltegravir using an original approach based on drug metabolism, protein binding, and penetration in seminal fluid: a pharmacokinetic substudy of the ANRS-163 ETRAL Study","volume":"39","author":"L\u00ea","year":"2019","journal-title":"Pharmacotherapy"},{"key":"2020061904535071600_dkaa090-B3","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1093\/jac\/dky198","article-title":"Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing","volume":"73","author":"Nguyen","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020061904535071600_dkaa090-B4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/jmv.21390","article-title":"LTR real-time PCR for HIV-1 DNA quantitation in blood cells for early diagnosis in infants born to seropositive mothers treated in HAART area (ANRS CO 01)","volume":"81","author":"Avettand-F\u00e8no\u00ebl","year":"2009","journal-title":"J Med Virol"},{"key":"2020061904535071600_dkaa090-B5","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"2020061904535071600_dkaa090-B6","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/QAI.0b013e31802b4956","article-title":"Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals","volume":"43","author":"Markowitz","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020061904535071600_dkaa090-B7","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1093\/jac\/dku557","article-title":"Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing","volume":"70","author":"Todesco","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020061904535071600_dkaa090-B8","doi-asserted-by":"crossref","first-page":"e86771","DOI":"10.1371\/journal.pone.0086771","article-title":"Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure","volume":"9","author":"Vandenhende","year":"2014","journal-title":"PLoS One"},{"key":"2020061904535071600_dkaa090-B9","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/jac\/dkq544","article-title":"Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia","volume":"66","author":"Wirden","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2020061904535071600_dkaa090-B10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jcv.2018.04.001","article-title":"Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment","volume":"104","author":"Armenia","year":"2018","journal-title":"J Clin Virol"},{"key":"2020061904535071600_dkaa090-B11","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/jac\/dky130","article-title":"Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART","volume":"73","author":"Nouchi","year":"2018","journal-title":"J Antimicrob Chemother"},{"author":"Orkin","key":"2020061904535071600_dkaa090-B12"},{"key":"2020061904535071600_dkaa090-B13","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"2020061904535071600_dkaa090-B14","doi-asserted-by":"crossref","first-page":"e41390","DOI":"10.1371\/journal.pone.0041390","article-title":"Similar evolution of cellular HIV-1 DNA level in darunavir\/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks","volume":"7","author":"Lambert-Niclot","year":"2012","journal-title":"PLoS One"},{"key":"2020061904535071600_dkaa090-B15","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/jac\/dkx068","article-title":"Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir\/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial","volume":"72","author":"Lombardi","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020061904535071600_dkaa090-B16","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1093\/jac\/dkq282","article-title":"Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123\u2013ETOILE)","volume":"65","author":"Avettand-Fenoel","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2020061904535071600_dkaa090-B17","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.2174\/1381612823666170329125820","article-title":"Factors associated with HIV testing and HIV treatment adherence: a systematic review","volume":"23","author":"Detsis","year":"2017","journal-title":"Curr Pharm Des"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1943\/33405130\/dkaa090.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/7\/1943\/33405130\/dkaa090.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T08:54:30Z","timestamp":1592556870000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/7\/1943\/5817086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,4,7]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa090","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2020,4,7]]}}}